China’s Akesobio sets ball rolling for HK listing
Akesobio, a Chinese biopharmaceuticals company, filed a draft prospectus for an IPO with Hong Kong’s stock exchange on Tuesday.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts